Cynthia Flowers was appointed President and Chief Executive Officer of Omeza Holdings in May of 2023 and also serves as a member of Omeza’s Board of Directors. She has been a strategic advisor to Omeza since January of 2023.
Ms. Flowers is the owner of EIR Advisory LLC, a life sciences advisory and strategic investment firm. Her tenure in the life sciences industry has spanned a multitude of leadership roles across numerous therapeutic areas. From February 2014 through November 2017, Ms. Flowers was President and Chief Executive Officer of Ipsen North America, where she led the transformation of the company as it evolved into the highest-growth subsidiary worldwide. Prior to joining Ipsen, she served as President of Eisai Pharmaceuticals, where she oversaw commercial operations, medical affairs and services, manufacturing, alliance management, and other strategic and operational functions. She has also held general management roles both domestically and internationally at Amgen Inc. and Johnson & Johnson. Ms. Flowers began her career as an oncology/critical care nurse.
Ms. Flowers currently serves on the board of, Hikma Pharmaceuticals PLC, a multigenerational generics company, G1 Therapeutics Inc., a commercial oncology biotechnology company and Lisata Therapeutics, a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other serious conditions. Ms. Flowers also serves as a Director for Relevate Holdings. She has held previous positions on numerous corporate and non-profit boards, including the Women’s Leadership Advisory Board for the John F. Kennedy School of Government at Harvard University and the board of directors for the Sarah Cannon Oncology Research Institute. Ms. Flowers holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S.N. from the University of Delaware.
